These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 12069157)

  • 1. Pharmaceutical strategies utilizing recombinant human serum albumin.
    Chuang VT; Kragh-Hansen U; Otagiri M
    Pharm Res; 2002 May; 19(5):569-77. PubMed ID: 12069157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics.
    Hirata K; Maruyama T; Watanabe H; Maeda H; Nakajou K; Iwao Y; Ishima Y; Katsumi H; Hashida M; Otagiri M
    J Control Release; 2010 Jul; 145(1):9-16. PubMed ID: 20304018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human serum albumin incorporating Tetrakis(o-pivalamido) phenylporphinatoiron(II) derivative as a totally synthetic O2-carrying hemoprotein.
    Tsuchida E; Komatsu T; Matsukawa Y; Hamamatsu K; Wu J
    Bioconjug Chem; 1999; 10(5):797-802. PubMed ID: 10502345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Serum Albumin and HER2-Binding Affibody Fusion Proteins for Targeted Delivery of Fatty Acid-Modified Molecules and Therapy.
    Dong D; Xia G; Li Z; Li Z
    Mol Pharm; 2016 Oct; 13(10):3370-3380. PubMed ID: 27546214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin clusters: structurally defined protein tetramer and oxygen carrier including thirty-two iron(II) porphyrins.
    Komatsu T; Oguro Y; Nakagawa A; Tsuchida E
    Biomacromolecules; 2005; 6(6):3397-403. PubMed ID: 16283771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vivo delivery of therapeutic proteins by genetically-modified cells: comparison of organoids and human serum albumin alginate-coated beads.
    Shinya E; Dervillez X; Edwards-Lévy F; Duret V; Brisson E; Ylisastigui L; Lévy MC; Cohen JH; Klatzmann D
    Biomed Pharmacother; 1999 Dec; 53(10):471-83. PubMed ID: 10665341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human serum albumin from recombinant DNA technology: challenges and strategies.
    Chen Z; He Y; Shi B; Yang D
    Biochim Biophys Acta; 2013 Dec; 1830(12):5515-25. PubMed ID: 23644036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progresses in recombinant human serum albumin].
    Manchu R; Zhang Y; Zhang Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Aug; 26(4):900-3. PubMed ID: 19813636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial oxygen carriers, hemoglobin vesicles and albumin-hemes, based on bioconjugate chemistry.
    Tsuchida E; Sou K; Nakagawa A; Sakai H; Komatsu T; Kobayashi K
    Bioconjug Chem; 2009 Aug; 20(8):1419-40. PubMed ID: 19206516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin.
    Matsushita S; Chuang VT; Kanazawa M; Tanase S; Kawai K; Maruyama T; Suenaga A; Otagiri M
    Pharm Res; 2006 May; 23(5):882-91. PubMed ID: 16715378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like Peptide 1 Conjugated to Recombinant Human Serum Albumin Variants with Modified Neonatal Fc Receptor Binding Properties. Impact on Molecular Structure and Half-Life.
    Bukrinski JT; Sønderby P; Antunes F; Andersen B; Schmidt EGW; Peters GHJ; Harris P
    Biochemistry; 2017 Sep; 56(36):4860-4870. PubMed ID: 28799326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants.
    Nakajou K; Watanabe H; Kragh-Hansen U; Maruyama T; Otagiri M
    Biochim Biophys Acta; 2003 Oct; 1623(2-3):88-97. PubMed ID: 14572906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules.
    Franssen EJ; Jansen RW; Vaalburg M; Meijer DK
    Biochem Pharmacol; 1993 Mar; 45(6):1215-26. PubMed ID: 8466542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical aspects of the recombinant human serum albumin dimer: structural characteristics, biological properties, and medical applications.
    Taguchi K; Chuang VT; Maruyama T; Otagiri M
    J Pharm Sci; 2012 Sep; 101(9):3033-46. PubMed ID: 22573538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate.
    Stehle G; Wunder A; Schrenk HH; Hartung G; Heene DL; Sinn H
    Anticancer Drugs; 1999 Sep; 10(8):785-90. PubMed ID: 10573211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo properties of recombinant human serum albumin from Pichia pastoris purified by a method of short processing time.
    Watanabe H; Yamasaki K; Kragh-Hansen U; Tanase S; Harada K; Suenaga A; Otagiri M
    Pharm Res; 2001 Dec; 18(12):1775-81. PubMed ID: 11785700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.
    Kratz F
    J Control Release; 2008 Dec; 132(3):171-83. PubMed ID: 18582981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation.
    Langer K; Anhorn MG; Steinhauser I; Dreis S; Celebi D; Schrickel N; Faust S; Vogel V
    Int J Pharm; 2008 Jan; 347(1-2):109-17. PubMed ID: 17681686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albumin-alginate-coated microspheres: resistance to steam sterilization and to lyophilization.
    Callewaert M; Laurent-Maquin D; Edwards-Lévy F
    Int J Pharm; 2007 Nov; 344(1-2):161-4. PubMed ID: 17604921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.